Soluble CCR2-Expressing Mesenchymal Stem Cells Inhibit Osteoarthritis Development and Progression

Area of Science:

• Biomedical Engineering
• Regenerative Medicine
• Orthopedics

Background:

• Osteoarthritis (OA) is a degenerative joint disease often treated with pain relievers or stem cells.
• Previous research indicated therapeutic effects of soluble C-C chemokine receptor type 2 (sCCR2) gene therapy for OA.
• Mesenchymal stem cells (MSCs) are explored for cartilage repair, but their efficacy can be enhanced.

Purpose of the Study:

• To evaluate if sCCR2-expressing MSCs (sCEMs) demonstrate superior efficacy over MSCs alone in an OA model.
• To investigate the therapeutic mechanisms of sCEMs in inhibiting OA progression.
• To assess the potential of sCEMs as an effective OA treatment.

Main Methods:

• An osteoarthritis (OA) rat model was established using monosodium iodoacetate induction.
• Soluble C-C chemokine receptor type 2 (sCCR2) was transfected into chondrocytes and MSCs to create sCEMs.
• In vitro and in vivo experiments were conducted, including analysis in MCP-1 conditional knockout mice.

Main Results:

• MCP-1 was found to inhibit chondrogenesis, while sCEMs demonstrated an improvement in chondrogenesis.
• sCEM treatment significantly suppressed OA disease development in the rat model.
• sCEM injections reduced pain, inflammation, and cartilage damage in OA rats compared to MOCK-MSCs.

Conclusions:

• sCEMs effectively inhibit MCP-1, leading to reduced pain and cartilage damage in OA.
• The findings suggest that sCEMs possess chondroprotective properties.
• Inhibiting MCP-1/CCR2 signaling presents a promising therapeutic strategy for osteoarthritis.